Suzuki, Naoki Tohoku University
Mori-Yoshimura, Madoka National Center of Neurology and Psychiatry
Yamashita, Satoshi Kumamoto University
Nakano, Satoshi Osaka City General Hospital
Murata, Ken-ya Wakayama Medical University
Mori, Megumi Wakayama Medical University
Inamori, Yukie Kagoshima University
Kimura, En Kumamoto University
Kusaka, Hirofumi Kansai Medical University
Kondo, Tomoyoshi Wakayama Medical University
Ito, Hidefumi Wakayama Medical University
Higuchi, Itsuro Kagoshima University
Hashiguchi, Akihiro Kagoshima University
Tateyama, Maki Tohoku University|National Hospital Organization Iwate National Hospital
Izumi, Rumiko Tohoku University
Ono, Hiroya Tohoku University|National Hospital Organization Iwate National Hospital
Kato, Masaaki Tohoku University|Southern Tohoku General Hospital
Warita, Hitoshi Tohoku University
Takahashi, Toshiaki Sendai-Nishitaga National Hospital
Nishino, Ichizo National Center of Neurology and Psychiatry
Aoki, Masashi Tohoku University
Sporadic inclusion body myositis
Background: Sporadic inclusion body myositis (sIBM) is the most prevalent muscle disease in elderly people, affecting the daily activities. sIBM is progressive with unknown cause and without effective treatment. In 2015, sIBM was classified as an intractable disease by the Japanese government, and the treatment cost was partly covered by the government. This study aimed to examine the changes in the number of patients with sIBM over the last 10 years and to elucidate the cross-sectional profile of Japanese patients with sIBM.
Methods: The number of sIBM patients was estimated through a reply-paid postcard questionnaire for attending physicians. Only patients diagnosed as “definite” or “probable” sIBM by clinical and biopsy sIBM criteria were included in this study (Lancet Neurol 6:620-631, 2007, Neuromuscul Disord 23:1044-1055, 2013). Additionally, a registered selfadministered questionnaire was also sent to 106 patients who agreed to reply via their attending physician, between November 2016 and March 2017.
Results: The number of patients diagnosed with sIBM for each 5-year period was 286 and 384 in 2011 and 2016, respectively. Inability to stand-up, cane-dependent gait, inability to open a plastic bottle, choking on food ingestion, and being wheelchair-bound should be included as sIBM milestones. Eight patients were positive for anti-hepatitis C virus antibody; three of them were administered interferon before sIBM onset. Steroids were administered to 33 patients (31.1%) and intravenous immunoglobulin to 46 patients (43.4%). From 2016 to 2017, total of 70 patients applied for the designated incurable disease medical expenses subsidy program. Although the treatment cost was partly covered by the government, many patients expressed psychological/mental and financial anxieties.
Conclusions: We determined the cross-sectional profile of Japanese patients with sIBM. Continuous support and prospective surveys are warranted.
Orphanet Journal of Rare Diseases
BioMed Central|Springer Nature
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
ojrd_14_155.pdf 1.32 MB